Mektovi FDA Approval History
FDA Approved: Yes (First approved June 27, 2018)
Brand name: Mektovi
Generic name: binimetinib
Dosage form: Tablets
Company: Array BioPharma Inc.
Treatment for: Melanoma, Metastatic, Non-Small Cell Lung Cancer
Mektovi (binimetinib) is a kinase inhibitor used for the treatment of melanoma and non-small cell lung cancer.
- Mektovi is indicated:
- in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
- in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
Development timeline for Mektovi
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
